Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-00217830
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF‑00217830 is an investigational small molecule drug developed by Pfizer for the treatment of schizophrenia. It acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors and as an antagonist at serotonin 5‑HT2A receptors. The compound was evaluated in phase II clinical trials for schizophrenia but development was discontinued due to either non-optimal pharmacokinetic properties or insufficient therapeutic efficacy[1][2][3][4][5].
- Other names
- 846032-02-88BC08N1MS5UNII 8BC08N1MS5UNII8BC08N1MS5UNII-8BC08N1MS5CHEMBL1774080CHEMBL-1774080CHEMBL 17740803,4-Dihydro-7-(4-(4-(1-naphthyl)piperazino)butoxy)-1,8-naphthyridine-2(1H)-one7-[4-(4-naphthalen-1-ylpiperazin-1-y)lbutoxy]-3,4-dihydro‑1H‑1,8‑naphthyridin‑2-one
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on PF-00217830.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-00217830.